Steven O'Day, MD

Chief Medical Officer of @Agenus_Bio
Physician and expert in IO, clinical drug development & melanoma.

[Agenus @Agenus_Bio]

Our CMO @ODayMD, reflects on #ColorectalCancerAwarenessMonth, recent #news for #botensilimab in #OvarianCancer, and our mission to develop an arsenal of #immunotherapy treatments.

#ColorectalCancer #oncology

https://t.co/zqMlgiFXgK

[Agenus @Agenus_Bio]

ICYMI: We are encouraged our phase 1a/1b study of #botensilimab (novel innate/ adaptive immune activator) + balstilimab (anti-PD-1-antibody) shows promise in heavily pretreated patients with #MSSCRC. #GI23

[Jennifer Buell @jbuell01]

#TheLegend ⁦@DrElkhoueiry⁩ #GI23 Botensilimab in MSS CRC median overall survival NOT reached!. Pathbreaking. ⁦@Agenus_Bio⁩ ⁦@MiNK_iNKT⁩

[Jennifer Buell @jbuell01]

WOW! @DrElkhoueiry presents BOTENSILMAB and survival in patients with MSS CRC! #GI23 @ASCO @Agenus_Bio @MiNK_iNKT

[Jennifer Buell @jbuell01]

Larry is center stage preparing for the @Agenus_Bio opening of the state of the art commercial manufacturing facility!

[Agenus @Agenus_Bio]

We are excited to announce the grand opening of our new fully integrated manufacturing facility at Emeryville, CA on January 17th. Stay tuned for more!

[Steven O'Day, MD @ODayMD]

Join us today as Agenus' Senior Director, Head of Drug Discovery, @dhanschand speaks today on the topic of Enhanced CTLA-4 Blockade alongside fellow industry leaders, and SITC series co-chairs James P. Allison and Alan J. Korman. https://t.co/rmTgaOFnY7

[Steven O'Day, MD @ODayMD]

I am looking forward to our #botensilimab oral presentation and the exciting Agenus event to follow

[Agenus @Agenus_Bio]

Agenus to Host “The Road Taken” R&D Event on November 12, 2022. Featured speakers include @ODayMD, @breelynwilkyMD, Dr. Michael Atkins, and more!
https://t.co/l3PybHLfHH

[Agenus @Agenus_Bio]

Agenus is pleased to announce the launch of our newly redesigned website. Follow us this week as we showcase some of its features!

[Steven O'Day, MD @ODayMD]

We are proud to announce that the first patient has been dosed in the Phase 1 study of AGEN1571, our wholly owned ILT2 antibody. AGEN1571 is part of our growing portfolio of clinical assets that are designed to broaden the promise of cancer immunotherapy. https://t.co/VJNloiCiGG

[Steven O'Day, MD @ODayMD]

To hear a deeper dive of the remarkable data and implications for the path forward, join @DrElkhoueiry , @DrMhidalgo, Heinz-Josef Lenz and myself today at 10am EST for our post-presentation webcast. #ESMOGI
https://t.co/VJbKZcwWpI

[Steven O'Day, MD @ODayMD]

Remarkable and unprecedented efficacy with Bot/bal combination in very IO cold advanced MSS CRC!
#WCGIC2022

[Steven O'Day, MD @ODayMD]

Just moments away from
@DrElkhoueiry‘s ESMO GI opening session presentation of Botensilimab in MSS CRC! @Agenus_Bio #WCGIC2022 @DrMhidalgo

[Steven O'Day, MD @ODayMD]

Less than a week away from @ESMOWorldGI in Barcelona! @DrElkhoueiry will be sharing clinical data on botensilimab & balstilimab in MSS CRC in a late-breaking oral session on June 29th. #WCGIC2022. More info at: https://t.co/wg8xuufqvH

[Steven O'Day, MD @ODayMD]

Excited to join the @Agenus_Bio Webcast on ESMO GI data. We will be hosting this webcast on June 29th at 10 AM ET following our presentation of clinical data on botensilimab in MSS #colorectalcancer at @ESMOWorldGI. Stay tuned for registration info! #WCGIC2022

[Agenus @Agenus_Bio]

Agenus’ CEO @garo_armen and CMO @ODayMD participated in a fireside chat at last week’s Jefferies Healthcare Conference in New York City. Listen in here: https://t.co/E2qaB0K32a

[Steven O'Day, MD @ODayMD]

Excited to share that @Jenniferbuell, CEO at MiNK Therapeutics, has been named #15 on @FastCompany & @Lesbiantech’s Annual #FCQueer50 list! Jen inspires me each day as we work side by side in our fight against cancer by harnessing the power of the immune system! Congratulations!

[MiNK Therapeutics @MiNK_iNKT]

In celebrating #pridemonth we are excited to announce our CEO, @jbuell01, was named #15 on @FastCompany & @lesbiantech’s 3rd Annual #FCQueer50 list!

"Jennifer has always encouraged her employees to be their most authentic selves at work." Check out more: https://t.co/k04vDVgb0v

[Steven O'Day, MD @ODayMD]

Beyond excited to announce 3 new clinical collaborations with @targovax, @oxfordbio & @ImmunoGenesis_. These partnerships offer combo's that may unlock the power of immunotherapy more broadly & potentially offer promising benefit to patients with treatment resistant solid tumors.

[Agenus @Agenus_Bio]

Agenus Advances Portfolio with 6 Clinical Collaborations
https://t.co/8zO4GqciLK

[Agenus @Agenus_Bio]

Agenus Advances Portfolio with 6 Clinical Collaborations
https://t.co/8zO4GqciLK

[Steven O'Day, MD @ODayMD]

My long time-time colleagues Michael Atkins (@LombardiCancer) & @ProfGLongMIA (MIA) will be giving 2 of 4 Plenary Abstracts this weekend at @ASCO. Michael is presenting melanoma data on DREAMseq IO vs BRAF/MEK sequencing, and Georgina updates on Rela+Nivo vs Nivo! Stay Tuned!